145 related articles for article (PubMed ID: 3000790)
1. Variable bioavailability following repeated oral doses of etoposide.
Harvey VJ; Slevin ML; Joel SP; Smythe MM; Johnston A; Wrigley PF
Eur J Cancer Clin Oncol; 1985 Nov; 21(11):1315-9. PubMed ID: 3000790
[TBL] [Abstract][Full Text] [Related]
2. The effect of dose on the bioavailability of oral etoposide.
Harvey VJ; Slevin ML; Joel SP; Johnston A; Wrigley PF
Cancer Chemother Pharmacol; 1986; 16(2):178-81. PubMed ID: 3004772
[TBL] [Abstract][Full Text] [Related]
3. The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide.
Harvey VJ; Slevin ML; Joel SP; Johnston A; Wrigley PF
Br J Cancer; 1985 Sep; 52(3):363-7. PubMed ID: 2994705
[TBL] [Abstract][Full Text] [Related]
4. Etoposide: a pharmacokinetic profile including an assessment of bioavailability.
Cunningham D; McTaggart L; Soukop M; Cummings J; Forrest GJ; Stuart JF
Med Oncol Tumor Pharmacother; 1986; 3(2):95-9. PubMed ID: 3018396
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide.
Stewart DJ; Nundy D; Maroun JA; Tetreault L; Prior J
Cancer Treat Rep; 1985 Mar; 69(3):269-73. PubMed ID: 3884152
[TBL] [Abstract][Full Text] [Related]
6. Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative.
Pagani O; Zucchetti M; Sessa C; de Jong J; D'Incalci M; De Fusco M; Kaeser-Fröhlich A; Hanauske A; Cavalli F
Cancer Chemother Pharmacol; 1996; 38(6):541-7. PubMed ID: 8823496
[TBL] [Abstract][Full Text] [Related]
7. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
[TBL] [Abstract][Full Text] [Related]
8. Bioavailability and pharmacokinetics of etoposide (VP-16).
Smyth RD; Pfeffer M; Scalzo A; Comis RL
Semin Oncol; 1985 Mar; 12(1 Suppl 2):48-51. PubMed ID: 3975657
[TBL] [Abstract][Full Text] [Related]
9. Etoposide infusions for treatment of metastatic lung cancer.
Steward WP; Thatcher N; Edmundson JM; Shiu W; Wilkinson PM
Cancer Treat Rep; 1984 Jun; 68(6):897-9. PubMed ID: 6329509
[TBL] [Abstract][Full Text] [Related]
10. Bioavailability of 50- and 75-mg oral etoposide in lung cancer patients.
Fujiwara Y; Ohune T; Okusaki K; Niitani K; Sumiyoshi H; Takemoto Y; Yamaoka N; Yamakido M
Cancer Chemother Pharmacol; 1996; 37(4):327-31. PubMed ID: 8548877
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
[TBL] [Abstract][Full Text] [Related]
12. Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial.
Waits TM; Johnson DH; Hainsworth JD; Hande KR; Thomas M; Greco FA
J Clin Oncol; 1992 Feb; 10(2):292-6. PubMed ID: 1310104
[TBL] [Abstract][Full Text] [Related]
13. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
14. Effect of grapefruit juice intake on etoposide bioavailability.
Reif S; Nicolson MC; Bisset D; Reid M; Kloft C; Jaehde U; McLeod HL
Eur J Clin Pharmacol; 2002 Oct; 58(7):491-4. PubMed ID: 12389073
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic optimisation of treatment with oral etoposide.
Toffoli G; Corona G; Basso B; Boiocchi M
Clin Pharmacokinet; 2004; 43(7):441-66. PubMed ID: 15139794
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity.
Clark PI; Slevin ML; Joel SP; Osborne RJ; Talbot DI; Johnson PW; Reznek R; Masud T; Gregory W; Wrigley PF
J Clin Oncol; 1994 Jul; 12(7):1427-35. PubMed ID: 8021734
[TBL] [Abstract][Full Text] [Related]
17. The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation.
Slevin ML; Joel SP; Whomsley R; Devenport K; Harvey VJ; Osborne RJ; Wrigley PF
Cancer Chemother Pharmacol; 1989; 24(5):329-31. PubMed ID: 2758563
[TBL] [Abstract][Full Text] [Related]
18. The clinical pharmacology of etoposide and teniposide.
Clark PI; Slevin ML
Clin Pharmacokinet; 1987 Apr; 12(4):223-52. PubMed ID: 3297462
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients.
Hande KR; Wedlund PJ; Noone RM; Wilkinson GR; Greco FA; Wolff SN
Cancer Res; 1984 Jan; 44(1):379-82. PubMed ID: 6690051
[TBL] [Abstract][Full Text] [Related]
20. [Effects of oral etoposide in small cell carcinoma of the lung].
Miyamoto H; Ito M; Araya Y; Takaoka K; Isobe H; Dosaka H; Kawakami Y; Shimizu T; Onodera S
Gan To Kagaku Ryoho; 1984 Jun; 11(6):1244-7. PubMed ID: 6329103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
